3BT-1

3BT-1 is an investigational **small-molecule** neurodegeneration drug candidate being developed by **Threebrooks Therapeutics** for **Alzheimer's disease** and potentially other CNS protein-aggregation disorders such as **Parkinson's disease**. Public company materials describe it as a **first-in-class agonist of the lysosomal ion channel TRPML1** that is intended to increase lysosomal calcium efflux, restore or enhance autophagy-lysosomal function, and promote clearance of pathological substrates including **amyloid-beta**, **tau aggregates**, and damaged mitochondria. The program has been described as orally deliverable and blood-brain-barrier penetrant, but publicly available information indicates it remained in **lead optimization / preclinical candidate selection** rather than clinical development as of the latest verifiable mentions.